BACKGROUND: Breast carcinoma and precancer are thought to start in the lining of the milk duct or lobule. METHODS: At 5weeks of age, rats received a intraperitoneal (ip) injection of MNU for carcinogenesis. After mammary tumors were identified macroscopically using fiberscope, the rats were treated with perductal (pd) or ip injection of paclitaxel tri-weekly. At 36 weeks after MNU injection, tumor burden (No. of >1cm palpable mammary tumors/rat), total number of mammary carcinoma, apoptosis (AI), and microvessel density (MVD) were measured. RESULTS: The administration of paclitaxel through the duct did not produce any toxic side effect. The tumor burden and total number of mammary carcinoma in the pd paclitaxel-treated group were significantly reduced compared to those seen in the ip paclitaxel-treated group. In addition, in the pd paclitaxel-treated group, AI was also increased and MVD was decreased, compared to those in the ip paclitaxel-treated group. CONCLUSION: Local administration of paclitaxel may be useful for treatment of breast cancer.
BACKGROUND:Breast carcinoma and precancer are thought to start in the lining of the milk duct or lobule. METHODS: At 5weeks of age, rats received a intraperitoneal (ip) injection of MNU for carcinogenesis. After mammary tumors were identified macroscopically using fiberscope, the rats were treated with perductal (pd) or ip injection of paclitaxel tri-weekly. At 36 weeks after MNU injection, tumor burden (No. of >1cm palpable mammary tumors/rat), total number of mammary carcinoma, apoptosis (AI), and microvessel density (MVD) were measured. RESULTS: The administration of paclitaxel through the duct did not produce any toxic side effect. The tumor burden and total number of mammary carcinoma in the pdpaclitaxel-treated group were significantly reduced compared to those seen in the ip paclitaxel-treated group. In addition, in the pdpaclitaxel-treated group, AI was also increased and MVD was decreased, compared to those in the ip paclitaxel-treated group. CONCLUSION: Local administration of paclitaxel may be useful for treatment of breast cancer.
Authors: Vered Stearns; Tsuyoshi Mori; Lisa K Jacobs; Nagi F Khouri; Edward Gabrielson; Takahiro Yoshida; Scott L Kominsky; David L Huso; Stacie Jeter; Penny Powers; Karineh Tarpinian; Regina J Brown; Julie R Lange; Michelle A Rudek; Zhe Zhang; Theodore N Tsangaris; Saraswati Sukumar Journal: Sci Transl Med Date: 2011-10-26 Impact factor: 17.956
Authors: James L Miller; Arianna P Bartlett; Rebecca M Harman; Prabin Dhangada Majhi; D Joseph Jerry; Gerlinde R Van de Walle Journal: J Mammary Gland Biol Neoplasia Date: 2022-07-29 Impact factor: 2.698
Authors: Neil Robertson; Lorenzo Sempere; Elizabeth Kenyon; Christiane Mallet; Kylie Smith; Jeremy Hix; Alan Halim; Jinda Fan; Anna Moore Journal: Mol Imaging Biol Date: 2022-09-07 Impact factor: 3.484
Authors: M Ellen Mahoney; Eva J Gordon; Jian Yu Rao; Yusheng Jin; Nola Hylton; Susan M Love Journal: Clin Breast Cancer Date: 2013-05-09 Impact factor: 3.225
Authors: Jolien S de Groot; Paul J van Diest; Miranda van Amersfoort; Eva J Vlug; Xiaojuan Pan; Natalie D Ter Hoeve; Hilde Rosing; Jos H Beijnen; Sameh A Youssef; Alain de Bruin; Jos Jonkers; Elsken van der Wall; Patrick W B Derksen Journal: Oncotarget Date: 2017-06-15